Current Pharmaceutical Analysis

Our screening flags Current Pharmaceutical Analysis as a possible predatory venue because its publisher appears on Beall's archive, which has been frozen since 2017. Treat this as a prompt to check carefully, not a verdict: verify against DOAJ and Think. Check. Submit before submitting.

Per our venue index, Current Pharmaceutical Analysis appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.

Papers in Current Pharmaceutical Analysis are cited about 4.1 times each within two years of publication, and Scimago places it in Q2, with an h-index of 35. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.

In the Scimago Journal Rank 2025 edition, Current Pharmaceutical Analysis is Q2 in 1 of its 4 subject categories and Q3 in the other 3. By category: Pharmaceutical Science: Q2, #93 of 195; Biophysics: Q3, #99 of 159; Molecular Medicine: Q3, #136 of 181; Biochemistry: Q3, #303 of 449. Its best category quartile is Q2. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Current Pharmaceutical Analysis is cited about 4.1 times per paper over two years, with an h-index of 35.

The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Current Pharmaceutical Analysis. The open equivalent is its best Scimago quartile, Q2 in Pharmaceutical Science, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.

Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.

Submission to acceptance for Current Pharmaceutical Analysis takes about 80 days (median) — Estimated from our library (n=16 papers). Treat it as indicative rather than a guarantee: editorial times vary by article type, reviewer availability and season, and a self-reported figure is the journal's own. We do not hold a peer-review acceptance rate for Current Pharmaceutical Analysis.